{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:07:25Z","timestamp":1790892445550,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Despite the increasing number of available medications, a significant proportion of IBD patients fail to achieve the current therapeutic targets. Uncontrolled IBD has a significant impact on patients\u2019 quality of life and on overall costs for the healthcare system. Given the complex pathophysiology of IBD, Combined Advanced Targeted Therapy (CATT), involving the combination of biologics\/small molecules, appears to have biological plausibility and is gaining increasing interest. The aim of this narrative review is to provide the current evidence regarding CATT in IBD and propose future developments in this field. Methods: Relevant literature evidence was searched with pertinent MeSH terms in the most important database. Results: Available evidence of CATT in IBD provides encouraging results in terms of efficacy and effectiveness, with an acceptable safety profile. CATT may represent a therapeutic solution for patients with \u201cdifficult-to-treat\u201d IBD or with concomitant immune-mediated inflammatory diseases. However, current data are restricted by an overall low level of evidence and by the short follow-up. Conclusions: There are no data concluding the superiority of one combination therapy over another. Various therapeutic schemes could be applied in the near future. Further studies are needed to provide recommendations and integrate this therapeutic strategy into everyday clinical practice.<\/jats:p>","DOI":"10.3390\/jcm14020590","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:24:56Z","timestamp":1737113096000},"page":"590","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"given":"Alice","family":"De Bernardi","sequence":"first","affiliation":[{"name":"IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-8549","authenticated-orcid":false,"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"IBD Centre, IRCCS Humanitas, Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Puricelli","sequence":"additional","affiliation":[{"name":"IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-1014","authenticated-orcid":false,"given":"Daniela","family":"Gilardi","sequence":"additional","affiliation":[{"name":"IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2534","authenticated-orcid":false,"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[{"name":"IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Parra, R.S., Chebli, J.M.F., Chebli, L.A., Lima, S.F.D., Neto, M.A.L., de Medeiros, T.R., Faria, F.M., Feitosa, M.R., Nigro, C.M.C., and F\u00e9res, O. (2023). Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093165"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17562848221115312","DOI":"10.1177\/17562848221115312","article-title":"Inflammatory bowel disease and immune-mediated inflammatory diseases: Looking at the less frequent associations","volume":"15","author":"Bezzio","year":"2022","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ibd\/izad182","article-title":"Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions","volume":"30","author":"Hunt","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bezzio, C., Brinch, D., Ribaldone, D.G., Cappello, M., Ruzzon, N., Vernero, M., Scalvini, D., Loy, L., Donghi, S., and Ciminnisi, S. (2024). Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study. Nutrients, 16.","DOI":"10.3390\/nu16233983"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Imbrizi, M., Magro, F., and Coy, C.S.R. (2023). Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091272"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD, (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: Mucosal, histological, transmural, barrier and complete healing","volume":"72","author":"Neurath","year":"2023","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.gastro.2022.10.014","article-title":"Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial","volume":"164","author":"Rath","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sands, B.E., Danese, S., Chapman, J.C., Gurjar, K., Grieve, S., Thakur, D., Griffith, J., Joshi, N., Kligys, K., and Dignass, A. (2024). Mucosal and Transmural Healing and Long-term Outcomes in Crohn\u2019s Disease. Inflamm. Bowel Dis., izae159.","DOI":"10.1093\/ibd\/izae159"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zurba, Y., Gros, B., and Shehab, M. (2023). Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030747"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10620-018-5381-0","article-title":"Usefulness of Thiopurine Monotherapy for Crohn\u2019s Disease in the Era of Biologics: A Long-Term Single-Center Experience","volume":"64","author":"Ferrer","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases\u2014A Danish nationwide cohort study","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: Drug levels and disease activity","volume":"11","author":"Chowers","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"VEGA Study Group. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn\u2019s Disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn\u2019s Disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic Review with Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"ref_33","unstructured":"(2024, November 29). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_34","first-page":"406","article-title":"Efficacy and Safety of Dual Biologic Therapy in Patients with Inflammatory Bowel Disease: A Review of the Literature","volume":"17","author":"Gold","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103331","DOI":"10.1016\/j.jaut.2024.103331","article-title":"Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Solitano","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Vernero, M., Saibeni, S., Scalvini, D., Cicalini, C., Chiarello, L., Nardi, S., Ribaldone, D.G., and Bezzio, C. (2024). Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041019"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jcag\/gwad032","article-title":"Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease","volume":"7","author":"Wetwittayakhlang","year":"2023","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cornet, N., Aboubakr, A., Ahmed, W., and Battat, R. (2024). Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update. Inflamm. Bowel Dis., izae189.","DOI":"10.1093\/ibd\/izae189"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjw116","article-title":"Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases","volume":"10","author":"Torres","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Battat, R., Chang, J.T., Loftus, E.V., and Sands, B.E. (2024). IBD Matchmaking\u2014Rational Combination Therapy. Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.cgh.2024.05.051"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhu, M., Feng, Q., Xu, X., Qiao, Y., Cui, Z., Yan, Y., and Ran, Z. (2020). Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn\u2019s disease, based on the L\u00e9mann index. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01575-7"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/590\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:54Z","timestamp":1759919454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14020590"],"URL":"https:\/\/doi.org\/10.3390\/jcm14020590","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}